Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep;46(9):1801-1808.
doi: 10.1111/jog.14269. Epub 2020 Jul 19.

Anti-Müllerian hormone and antral follicle count differ in their ability to predict cumulative treatment outcomes of the first complete ovarian stimulation cycle in patients from POSEIDON groups 3 and 4

Luxin Liu  1   2 , Canquan Zhou  1   2
Affiliations

Anti-Müllerian hormone and antral follicle count differ in their ability to predict cumulative treatment outcomes of the first complete ovarian stimulation cycle in patients from POSEIDON groups 3 and 4

Luxin Liu et al. J Obstet Gynaecol Res. 2020 Sep.

Abstract

Aim: To explore the ability of anti-Müllerian hormone and antral follicle count to predict cumulative live birth and clinical pregnancy in the first complete ovarian stimulation cycle among patients from POSEIDON (Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number) groups 3-4.

Methods: A single-center retrospective study was conducted on 260 patients in POSEIDON groups 3-4 (antral follicle count <5 and/or anti-Müllerian hormone <1.2 ng/mL) who first underwent complete in vitro fertilization/intracytoplasmic sperm injection cycles between January 2016 and June 2018. The main outcomes were cumulative live birth rate and cumulative clinical pregnancy rate.

Results: Of 260 patients, 113 (43.5%) achieved clinical pregnancy and 82 (31.5%) achieved live birth in their first complete ovarian stimulation cycles. With multivariate regression analysis, age and antral follicle count were significantly correlated with cumulative clinical pregnancy, whereas age and anti-Müllerian hormone were significantly associated with cumulative live birth. Receiver operating characteristic curve analysis demonstrated that age had the highest accuracy for the prediction of cumulative treatment outcomes. The optimal cut-off value of age was 40.5 and that of antral follicle count was 2.5 for predicting cumulative clinical pregnancy. The optimal cut-off value of age was 36.5 and that of anti-Müllerian hormone was 0.725 for predicting cumulative live birth.

Conclusion: Our findings indicate that anti-Müllerian hormone is a better predictor of cumulative live birth than antral follicle count, independent of age, in the first complete ovarian stimulation cycle of in vitro fertilization/intracytoplasmic sperm injection among patients in POSEIDON groups 3-4.

Keywords: Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number stratification; anti-Müllerian hormone; antral follicle count; cumulative live birth; in vitro fertilization.

PubMed Disclaimer

References

    1. Haahr T, Esteves SC, Humaidan P. Individualized controlled ovarian stimulation in expected poor-responders: An update. Reprod Biol Endocrinol 2018; 16: 20.
    1. Ferraretti AP, La Marca A, Fauser BC et al. ESHRE consensus on the definition of ‘poor response’ to ovarian stimulation for in vitro fertilization: The Bologna criteria. Hum Reprod 2011; 26: 1616-1624.
    1. Poseidon Group (Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number), Alviggi C, Andersen CY et al. A new more detailed stratification of low responders to ovarian stimulation: From a poor ovarian response to a low prognosis concept. Fertil Steril 2016; 105: 1452-1453.
    1. Humaidan P, Alviggi C, Fischer R, Esteves SC. The novel POSEIDON stratification of ‘Low prognosis patients in assisted reproductive technology’ and its proposed marker of successful outcome. F1000Res 2016; 5: 2911.
    1. Conforti A, Esteves SC, Picarelli S et al. Novel approaches for diagnosis and management of low prognosis patients in assisted reproductive technology: The POSEIDON concept. Panminerva Med 2019; 61: 24-29.

Substances

LinkOut - more resources